目的 了解安徽省新型冠状病毒(简称新冠病毒)感染者的重复感染情况,分析重复感染的影响因素,为识别重复感染的高风险人群,制定新时期的疫情防控政策提供科学依据。方法 随机抽取2020年1月1日至2022年10月31日在安徽省内居住且新冠病毒核酸阳性的部分人群进行问卷调查,收集调查对象一般人口学特征、疫苗接种信息、发病和就诊情况,以及在2022年12月至2023年2月期间新冠病毒重复感染情况,采用logistic回归模型分析重复感染的影响因素。结果 共调查2 190名既往新冠病毒感染者,男性和女性分别占47.99%(1 051/2 190)和52.01%(1 139/2 190)。首次感染临床分型中,无症状型占比最高,为64.47%(1 412/2 190),其次是轻型、中型和重型/危重型,分别占17.85%(391/2 190)、16.35%(358/2 190)和1.33%(29/2 190)。2022年12月之后重复感染新冠病毒者(即有临床症状和/或核酸/抗原阳性者)占24.84%(544/2 190)。logistic回归分析显示首次临床分型为重型/危重型(OR=2.945,95%CI:1.147~7.560)、未完成新冠疫苗基础免疫(OR=1.640,95%CI:1.014~2.654)、首次感染距重复感染发现时间＞24个月(OR=11.491,95%CI:8.251~16.004)和13~24个月 (OR=7.000,95%CI:3.554~13.804)是新冠病毒重复感染的危险因素。结论 新冠病毒重复感染率较高,且首次感染的临床分型、首次感染距重复感染发现时间以及新冠疫苗基础免疫接种是影响重复感染的重要因素。
Abstract
Objective To investigate the rate of SARS-CoV-2 reinfection in Anhui Province,China,and to analyze the influencing factors of reinfection,so as to provide a scientific basis for high-risk groups of reinfection identification and formulation of targeted intervention measure in the new period. Methods People who living in Anhui Province from January 1,2020 to October 31,2022 and tested positive for SARS-CoV-2 nucleic acid were randomly selected for the questionnaire survey.The general demographic characteristics,vaccination status,onset and medical attendance,and repeated infection status from December 2022 to February 2023 were collected.The influencing factors of reinfection were analyzed by logistic regression. Results A total of 2 190 people with previous SARS-CoV-2 infection were investigated,of uhom 47.99% (1 051/2 190) were male and 52.01% (1 139/2 190) were female.The highest proportion of clinical types of the first infection was asymptomatic,accounting for 64.47% (1 412/2 190),followed by mild,middle and severe/critical types,accounting for 17.85% (391/2 190),16.35% (358/2 190) and 1.33% (29/2 190),respectively.24.84% (544/2 190) were reinfected with SARS-CoV-2 after December 2022 (with clinical symptoms or positive nucleic acid/antigen test).Logistic regression analysis showed that the patients with severe/critical illness for the first time infection,the patients who have not completed the basic immunization of SARS-Cov-2 (OR=1.640,95%CI:1.014-2.654),the time since first time infection was more than two years(OR=11.491,95%CI:8.251-16.004) and between thirteen to twenty-four months(OR=7.000,95%CI:3.554-13.804) were the risk factors of reinfection. Conclusion High risk of repeated infection of SARS-CoV-2 and the clinical classification of the first infection,the time since the first infection and the basic immunization with SARS-CoV-2 vaccine are the main factors affecting the repeated infection.
关键词
新型冠状病毒 /
重复感染 /
疫苗接种
Key words
SARS-CoV-2 /
Reinfection /
Vaccination
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Lan J,Ge J,Yu J,et al.Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor[J].Nature,2020,581(7807):215-220.
[2] Wu F,Zhao S,Yu B,et al.A new coronavirus associated with human respiratory disease in China[J].Nature,2020,579(7798):265-269.
[3] 郭倩,黄明月,龚磊,等.新型冠状病毒肺炎最新研究进展[J].安徽预防医学杂志,2022,28(3):234-238+254.
[4] World Health Orgnation.Daily cases and deaths of COVID-19 by date reported to WHO.[EB/OL].(2023-09-06)[2023-10-08].https://www.who.int/zh/mega-menu/data/dashboards/covid-19-dashboard..
[5] Goldman JD,Wang K,Röltgen K,et al.Reinfection with SARS-CoV-2 and waning humoral immunity:a case report[J].Vaccines,2022,11(1):5.
[6] Bertrand D,Candon S.Protection against SARS-CoV-2 variants with COVID-19 vaccination in kidney transplant recipients[J].Clin J Am Soc Nephrol,2022,17(1):3-5.
[7] Altmann DM,Boyton RJ.SARS-Cov-2 immune waning and reinfection in care-home settings[J].Lancet Healthy Longev,2021,2(12):e776-e777.
[8] 戴映雪,王瑶,杜训波,等.成都市新冠病毒既往感染者重复感染Omicron变异株情况分析[J].中国公共卫生,2023,39(4):442-447.
[9] Mao YJ,Wang W,Ma J,et al.Reinfection rates among patients previously infected by SARS-CoV-2:systematic review and meta-analysis[J].Chin Med J,2022,135(2):145-152.
[10] Al-Ahmad M,Alowayesh M,Al Awadi A,et al.Nationwide study of rates of reinfection with SARS-CoV-2 among adults in Kuwait[J].East Mediterr Health J,2023,29(2):146-150.
[11] Cohen D,Izak M,Stoyanov E,et al.Predictors of reinfection with pre-Omicron and Omicron variants of concern among individuals who recovered from COVID-19 in the first year of the pandemic[J].Int J Infect Dis,2023,132:72-79.
[12] Jung C,Kmiec D,Koepke L,et al.Omicron:what makes the latest SARS-CoV-2 variant of concern so concerning?[J].J Virol,2022,96(6):e0207721.
[13] Schub D,Klemis V,Schneitler S,et al.High levels of SARS-CoV-2-specific T cells with restricted functionality in severe courses of COVID-19[J].JCI Insight,2020,5(20):e142167.
[14] 张戈,张安冉,贾逸林,等.上海市浦东新区新冠病毒重复感染情况分析[J/OL].上海预防医学,2023:1-14.(2023-09-01)[2024-02-27].https://kns.cnki.net/kcms/detail/31.1635.R.20230831.1735.002.html.
[15] 陈雪琴,侯玉珍,蔡春生,等.中山市新冠病毒既往感染者再次感染情况调查[J].现代预防医学,2023,50(15):2844-2847+2880.
[16] Michlmayr D,Hansen CH,Gubbels SM,et al.Observed protection against SARS-CoV-2 reinfection following a primary infection:a Danish cohort study among unvaccinated using two years of nationwide PCR-test data[J].Lancet Reg Health Eur,2022,20:100452.
[17] Team C1 F.Past SARS-CoV-2 infection protection against re-infection:a systematic review and meta-analysis[J].Lancet,2023,401(10379):833-842.
[18] Xie T,Lu S,He Z,et al.Three doses of prototypic SARS-CoV-2 inactivated vaccine induce cross-protection against its variants of concern[J].Signal Transduct Target Ther,2022,7(1):61.
[19] Alser M ,Waisberg E.Is it of any positive being COVID-19 positive?:cross-protection hypothesis [J].Eur J Immunol,2022,52:315-328.
[20] 解韬.劳动年龄人口变化及其影响因素分析——以广州市为例[J].城市观察,2020(5):53-66.
[21] 解韬,任拓宇.广东省劳动年龄人口变动特征及其成因分析[J].南方人口,2020,35(4):17-27.
[22] Nagao M,Matsumura Y,Yamamoto M,et al.Incidence of and risk factors for suspected COVID-19 reinfection in Kyoto City:a population-based epidemiological study[J].Eur J Clin Microbiol Infect Dis,2023,42(8):973-979.
[23] Bastard J,Taisne B,Figoni J,et al.Impact of the Omicron variant on SARS-CoV-2 reinfections in France,March 2021 to February 2022[J].Euro Surveill,2022,27(13):2200247.
基金
2022年安徽省新冠病毒科研应急攻关项目(2022e07020071)
PDF(814 KB)
